Polymorphisms associated with hypertension

• US 6,525,185 B1
• Filed: 05/03/1999
• Issued: 02/25/2003
• Est. Priority Date: 05/07/1998
• Status: Active Grant

• Current Assignee: Case Western University, Affymetrix, Inc. (Thermo Fisher Scientific Incorporated)
• Original Assignee: Affymetrix, Inc. (Thermo Fisher Scientific Incorporated)
• Inventors: Halushka, Marc Kenneth, Chakravarti, Aravinda, Fan, Jian Bing
• Primary Examiner(s): Horlick, Kenneth R.
• Assistant Examiner(s): KIM, YOUNG J
• Application Number:
  US09/304,232
• Time in Patent Office: 1,394 Days
• Field of Search: 435/6, 435/226, 435/91.1, 536/23.1, 536/24.3
• US Class Current: 536/23.1
• CPC Class Codes: C07K 14/72 for hormones for neuromediators C07K14/70571
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 2600/156 Polymorphic or mutational markers

Abstract

The invention discloses a collection of polymorphic sites in genes know or suspected to have a role in hypertension. The invention provides nucleic acids including such polymorphic sites. The nucleic acids can be used as probes or primers or for expressing variant proteins. The invention also provide methods of analyzing the polymorphic forms occupying the polymorphic sites.

Claims

1. A nucleic acid of between 10 and 100 bases comprising at least 10 contiguous nucleotides including a polymorphic site from a sequence shown in Table 1, column 8 or the complement thereof, wherein the sequence is selected from the group consisting of SEQ ID NOS:

2, 3, 4, 13, 15, 16, 20, 21, 25, and 26.

2. The nucleic acid of claim 1 that is DNA.

3. The nucleic acid of claim 1 that is RNA.

4. The nucleic acid of claim 1 that is less than 50 bases.

5. The nucleic acid of claim 1 that is less than 20 bases.

6. The nucleic acid of claim 1, wherein the polymorphic form occupying the polymorphic site is a reference base shown in Table 1, column 3.

7. The nucleic acid of claim 1, wherein the polymorphic form occupying the polymorphic site is an alternative base shown in Table 1, column 5.

8. The nucleic acid of claim 7, wherein the alternative base correlates with hypertension or susceptibility thereto.

9. The nucleic acid of claim 1, which is from a gene encoding alpha-adducin.

10. The nucleic acid of claim 1, which is from a gene encoding an angiotensin converting protein.

11. An allele-specific oligonucleotide of no more than 100 bases that hybridizes to a sequence including a polymorphic site shown in Table 1 or the complement thereof, wherein the sequence is selected from the group consisting of SEQ ID NOS:

2, 3, 4, 13, 15, 16, 20, 21, 25, and 26.

12. The allele-specific oligonucleotide of claim 11 that is a probe.

13. An isolated nucleic acid comprising a sequence of Table 1, column 8 or the complement thereof, wherein the polymorphic site within the sequence or its complement is occupied by a base other than the reference base shown in Table 1, column 3, and wherein the sequence is selected from the group consisting of SEQ ID NOS:

2, 3, 4, 13, 15, 16, 20, 21, 25, and 26.